Sequenom, Inc. has announced the sales of multiple MassARRAY® systems in China. Sequenom's new MassARRAY customers include the Beijing Genomics Institute (BGI), Asia's largest genetic sequencing center, which plans to initially use the system for its advanced research in viral genetics and later for human genetic projects, and CapitalBio, a China-based life science service company with capacities for whole genome association studies, which plans to expand into the fine mapping market.
Dr. Wang Wei, BGI Director of Viral Genotyping, said, "We chose Sequenom's MassARRAY technology because it features a unique combination of through-put, accuracy, sensitivity, reproducibility and cost efficiency. It is particularly suitable for the high-volume viral genotyping project and other population screening projects we plan to undertake in the near future."
Sequenom's President and CEO Harry Stylli, Ph.D. said, "We view the Chinese market as a very attractive opportunity to expand our genetic analysis business. We believe that sales to the distinguished research institute BGI and a leading service provider CapitalBio demonstrate the effectiveness of our activities to penetrate the growing Chinese market."